3HR Regimen Dosing and Specifications for LTBI
For a non-pregnant adult with latent tuberculosis infection and no known drug resistance, administer isoniazid 300 mg plus rifampin 600 mg daily for 3 months (90 doses total). 1
Specific Dosing Parameters
Daily administration:
- Isoniazid: 300 mg once daily (5 mg/kg up to 300 mg maximum) 2
- Rifampin: 600 mg once daily 3
- Duration: 3 months (approximately 90 consecutive daily doses)
Key Specifications and Monitoring
Before initiating treatment:
- Rule out active tuberculosis disease through clinical evaluation and chest imaging 1
- Obtain baseline liver function tests if patient is >35 years old, has pre-existing liver disease, uses alcohol regularly, or has other hepatotoxicity risk factors 2
- Confirm the presumed M. tuberculosis strain is susceptible to both isoniazid and rifampin 1
During treatment:
- Monthly clinical monitoring for adherence and adverse effects 4
- Liver function testing at 1 month and whenever symptoms of hepatotoxicity develop 4
- Pyridoxine (vitamin B6) supplementation is recommended for patients at risk of peripheral neuropathy (diabetics, alcoholics, malnourished, pregnant women) 2
Critical Safety Considerations
Hepatotoxicity monitoring: The 3HR regimen demonstrates hepatotoxicity rates of 29-44%, though severe hepatotoxicity requiring treatment discontinuation occurs in only 1.9-5.8% of patients 5, 4. This is comparable to or lower than 6-month isoniazid monotherapy. Hepatic adverse events are the most common reason for discontinuation (73.2% of all adverse events) 6.
Drug interactions: Rifampin is a potent inducer of hepatic enzymes and interacts with numerous medications including oral contraceptives, anticoagulants, antiretrovirals, and immunosuppressants. Review all concurrent medications before prescribing 3.
Common pitfall: Do not confuse rifampin with rifapentine—these drugs are NOT interchangeable. The 3HR regimen specifically uses rifampin (daily dosing), not rifapentine (which is used in the weekly 3HP regimen) 1.
Treatment Completion and Effectiveness
The 3HR regimen achieves superior completion rates compared to longer isoniazid monotherapy: 90-92.5% completion with 3HR versus 75.6-84.9% with 6-month isoniazid 5, 4. The shorter duration and lower pill burden drive this improved adherence. Recent data from 2025 shows 73.5% completion in real-world implementation, with adverse events being the primary barrier to completion 6.
Effectiveness: Both 3HR and 6-month isoniazid demonstrate full effectiveness in preventing progression to active tuberculosis when completed 4. The 3HR regimen is designated as one of three preferred rifamycin-based regimens by CDC/NTCA guidelines based on effectiveness, safety, and high completion rates 1.
Contraindications
- Pregnancy (rifampin is acceptable, but the combination requires individualized assessment; pyrazinamide is not recommended due to inadequate teratogenicity data, though this applies to different regimens) 2
- Known resistance to isoniazid or rifampin 1
- Active tuberculosis disease (must be excluded before initiating) 1
- Severe hepatic impairment
Administration Strategy
While directly observed therapy (DOT) can be considered for all patients to ensure adherence 2, the 3HR regimen is typically self-administered given its daily dosing schedule. However, patients with adherence concerns may benefit from DOT or enhanced monitoring strategies 1. The fixed-dose combination formulation, when available, may further reduce the risk of acquired drug resistance even with treatment interruptions 7.